<DOC>
	<DOCNO>NCT00179699</DOCNO>
	<brief_summary>Study deteremine MTD evaluate safety profile oral lenalidomide day 1-14 combined pemetrexed day 1 21 day cycle . Subjects continue study documention disease progression .</brief_summary>
	<brief_title>Phase I Open-Label , Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide ( RevlimidÂ® , CC-5013 ) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Subjects must understand voluntarily sign informed consent document . 2 . Age &gt; or= 18 year time signing informed consent form . 3 . Subjects must able adhere study visit schedule protocol requirement . 4 . Histological cytologic documentation advance NSCLC . 5 . Radiographic clinical evidence measurable advanced NSCLC . Subjects must measurable disease least 2 cm diameter . 6 . Subjects must treat progress follow chemotherapy . 7 . ECOG performance status 0 1 ( Appendix I : ECOG Performance Status Scale ) . 8 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . 1 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) 2 . Platelet count &lt; 100,000 cells/mm3 ( 100 x 109/L ) 3 . Serum creatinine &gt; 1.5 mg/dL ( 133 mmol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; = 1.5 mg/dL ( 26 mmol/L ) 2 . Any serious medical condition psychiatric illness place subject unacceptable risk study participation would prevent subject signing informed consent . 3 . Prior history malignancy ( except basal cell squamous cell carcinoma carcinoma situ breast ) unless subject free disease &gt; 1 year . 4 . Known brain leptomeningeal disease ( CT scan MRI brain required case clinical suspicion central nervous system involvement ) . 5 . More one prior chemotherapy advance NSCLC . 6 . Concurrent use anticancer agent . 7 . Any prior use lenalidomide . 8 . Pregnant lactating female . 9 . Prior &gt; = grade 3 rash desquamating ( blister ) rash take thalidomide . 10 . Prior &gt; = grade 3 allergic reaction/hypersensitivity thalidomide . 11 . Use standard/experimental anticancer drug therapy within 28 day initiation study drug therapy . 12 . Known Hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>cc-5013</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>revlimid</keyword>
	<keyword>celgene</keyword>
	<keyword>cc5013</keyword>
</DOC>